Your Search Results

Assessing coronaries in ACS with intracoronary imaging

21 May 2026 – From EuroPCR 2026

This session highlights the critical role of intracoronary imaging in evaluating acute coronary syndromes (ACS). It discusses the management of complex lesion morphologies involving calcium and thrombus, the diagnostic power of OCT in decision-making, challenges beyond angiography in right coronary artery pathology, and the identification of...

TAVI sub-studies - Beyond the primary endpoint

21 May 2026 – From EuroPCR 2026

This session reviews key sub-studies from major TAVI trials that extend beyond primary endpoints to provide a deeper understanding of valve performance and patient outcomes. It covers comparisons between balloon-expandable and self-expanding valves, long-term real-world data on the Myval valve, echocardiographic outcomes, composite endpoint analyses, and...

TAVI sub-studies - Beyond the primary endpoint

Diagnosis and management of INOCA and ANOCA

21 May 2026 – From EuroPCR 2026

This session focuses on the diagnosis and management of ischemia and angina with non-obstructive coronary arteries (INOCA and ANOCA). It presents safety data from coronary function testing, patient outcomes after comprehensive ischemia assessment, and endotype-specific treatment effects. Further topics include coronary sinus reducer therapy, the impact...

New evidence in coronary physiology for microvascular assessment

21 May 2026 – From EuroPCR 2026

This session highlights new evidence in coronary physiology related to microvascular assessment. Topics include endothelial dysfunction in angina with non-obstructive arteries, the prognostic value of microvascular resistance metrics, natural history studies, and trials aimed at standardizing management of microvascular dysfunction.

New evidence in coronary physiology for microvascular assessment

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe

01 Aug 2025

The CLEAR SYNERGY (OASIS 9) Trial: A 2x2 factorial randomized controlled trial of colchicine versus placebo and spironolactone versus placebo in patients with myocardial infarction

18 Nov 2024

Mirvat Alasnag provides her take on the CLEAR SYNERGY trial presented by Sanjit S Jolly at AHA 2024 in Chicago.